Quince Therapeutics, Inc. (QNCX) Stock Forecast
QNCX analyst forecast
as of October 18, 2026- Analyst consensus
- —
- Price target
- $75.00 average of analyst targets
- Upside to target
- +134.2% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.83
- 52-week range
- $16.00 – $880.00
QNCX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
QNCX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.20 | −$1.40 | −$0.83 | −$50.00 | +97.6% | 3 |
| Current fiscal year (2026) | −$3.65 | −$8.00 | −$0.96 | −$336.00 | +98.9% | 3 |
| Next fiscal year (2027) | −$4.68 | −$6.60 | −$3.49 | −$3.65 | −28.2% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
QNCX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 7 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 8 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 8 |
QNCX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
QNCX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$8.80 | −$1.40 | −$1.10 | −$1.20 | −$1.20 | −86.4% | 0 up · 0 down |
| Current fiscal year (2026) | −$5.30 | −$1.48 | −$3.65 | −$3.65 | −$3.65 | −31.1% | 0 up · 0 down |
| Next fiscal year (2027) | −$26.10 | −$5.76 | −$4.68 | −$4.68 | −$4.68 | −82.1% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
QNCX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; QNCX beat in 2 of 9.
What analysts expect from QNCX
The average price target is $75.00, 134.2% above the latest close of $32.03. Analysts expect earnings of −$3.65 per share for 2026, +98.9% from a year earlier. For 2027 the average estimate is −$4.68 per share. Quince Therapeutics beat the EPS estimate in 2 of the last 9 quarters.
Related: QNCX income statement, QNCX key metrics, QNCX chart. See the QNCX stock overview for the latest quote and news.
QNCX forecast FAQ
What is Quince Therapeutics's price target?
The average analyst price target for Quince Therapeutics is $75.00, 134.2% above the latest close of $32.03.
What is Quince Therapeutics's EPS forecast?
Analysts forecast −$3.65 per share for 2026 (range −$8.00 to −$0.96); for 2027 the estimate is −$4.68.
When does Quince Therapeutics report earnings?
Quince Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.83.
Does Quince Therapeutics usually beat earnings estimates?
Quince Therapeutics reported EPS at or above the analyst estimate in 2 of the last 9 quarters.